2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisJasvinder A. Singh, Kenneth G. Saag, Daniel E. Fürst et al.|Arthritis Care & Research|2012Cited by 1.8k
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guidelineCharles L. Daley, Kevin Winthrop|European Respiratory Journal|2020Cited by 876
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice GuidelineCharles L. Daley, Kevin Winthrop|Clinical Infectious Diseases|2020Cited by 828
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized StudyDavid E. Griffith, Kevin Winthrop, Gina Eagle et al.|American Journal of Respiratory and Critical Care Medicine|2018Cited by 343
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, William G Dixon et al.|Annals of the Rheumatic Diseases|2016Cited by 331